ROYAL CANIN® is part of the Royal Canin Division in the Mars, Incorporated group, and a global leader in Health Through Nutrition for cats and dogs fulfilling its Purpose: A BETTER WORLD FOR PETS. Founded in 1968 by French veterinarian, Dr. Jean Cathary, ROYAL CANIN® designs precise, science-based nutrition for cats and dogs available at pet specialty retailers and veterinary practices worldwide.
Over the years, ROYAL CANIN® has pushed the limits of nutrition and knowledge in partnership with pet professionals, including breeders and veterinarians. Its unique business approach puts the nutritional requirements of cats and dogs at the heart of innovation. Pet’s age, lifestyle, size, breed, and sensitivities are studied through science and observation to produce diets that meet their specific needs.
ROYAL CANIN® generates value not only for pets, but also for people and the planet. This means being mutually beneficial to the ecosystem, empowering Associates, building enduring relationships with stakeholders, and always thinking about how to ensure a viable future for generations to come.
Shenzhen Mindray Animal Medical Technology Co., LTD. (short as Mindray Animal Medical), as a new wholly-owned subsidiary of Mindray Group, is dedicated to providing advanced medical devices and comprehensive solutions for animals, including companion animals, farm animals, equine, and exotic animals.
We are committed to offering equal access to high-quality healthcare by meeting different demands of veterinarians to care for a wide variety of animals.
With a broad portfolio of products covering medical imaging systems, patient monitoring & life support, and In-Vitro diagnostics of animals, we're improving the healthcare experience for animals and enhancing confidence for animal caregivers.
Zoetis, Inc., formerly the animal health business unit of Pfizer Inc., is now an independent global leader in animal health. We have accumulated more than 70 years of experience and have more than 1,600 scientists around the world dedicated to pharmaceutical development, with global sales of $8.5 billion in 2023, making us the only animal health company to be listed in the U.S. Fortune 500.
Zoetis’ product portfolio covers animal vaccines, parasiticides, antibiotics, diagnostic reagents, anti-emetic medicine, anesthesia and sedation, anti-itch drugs, therapeutic monoclonal antibodies, etc. In May 2018, Zoetis invested 2 billion US dollars to complete the acquisition of Abaxis, the world's top listed diagnostic medical company, took the lead in becoming the first animal health company to be able to provide "diagnosis - prevention - treatment" multi-faceted solutions; Since 2019, Zoetis had acquired a number of famous reference laboratories in the United States (including Phoenix, ZNLabs and Ethos), and in 2022 invested in the establishment of a third-party testing laboratory in Beijing and Shanghai in China, greatly enriching the scope of diagnostic services.
Adhering to the spirit of scientific research and innovation, Zoetis officially launched the world's first veterinary JAK inhibitor Apoquel® in 2013, the world’s first monoclonal antibody Cytopoint® for canine atopic dermatitis in 2016, followed by the launch of the first monoclonal antibody Librela® for canine with osteoarthritis pain, the first monoclonal antibody Solensia® for feline with osteoarthritis pain, new generation parasiticide of isooxazoline Revolution Plus® and Simparica Trio® from 2019 to 2021, leading veterinary medicine into a new era.
At the Purina Institute, we transform nutrition science into actionable information that you can put into practice to benefit your patients. And through the Purina Institute’s extensive online resources, publications and scientific programs, you can stay armed with the unbiased, science-based nutrition information you need to help pets live better, longer lives.
To learn more, visit PurinaInstitute.com and follow us on social media.
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Boehringer Ingelheim entered Chinese market in 1994, with its headquarters in Shanghai. It operates nationwide and currently has about 3,700 employees across the country. Boehringer Ingelheim China focuses on Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing with full value chain footprint including R&D, manufacturing, commercial operation and external innovation collaboration. China is a focus market and source of innovation for Boehringer Ingelheim. China’s needs have been incorporated into the company’s global R&D strategy. The company aims to bring more and better innovative products earlier to the Chinese patients, contribute to the high-quality development of China’s healthcare industry, and comprehensively improve the health of human and animals. In recent years, the company has achieved continuous development, and has been certified as “China Top Employer” for eleven consecutive years. For more information, please visit: www.boehringer-ingelheim.cn, www.boehringer-ingelheim.com
BEIJING JI CHONG BIOTECH has always adhered to the principle of "Sell No Food until it is Okayed by the dogs and cats".
With 20 years of dedication to the pet industry, JI CHONG is a professional company renowned for its commitment to pet nutrition and health. Based on the international cutting-edge nutrition science research and development, and collaborating with international expert team, we launch Golden Prince® Veterinary Diet in August 2023. Since its launch, Golden Prince® has gained high recognition from veterinarians. There are currently 12 veterinary diets, in which the nutritional elements are scientifically adjusted to meet the special nutritional needs of pets under specific physiological and pathological conditions. Each product complies with the principle of complete and balanced diet, fully meets the nutritional needs of pets under disease conditions, and provides nutritional solutions for veterinarians. We will continue to develop new products based on the development of Chinese pet clinical diagnosis and treatment, meeting the needs of clinical veterinarians, helping our beloved pets enjoy a better and longer life by our unwavering commitment to the nutrition, health and well-being.
JI CHONG adheres to the corporate spirit of “SCIENCE, QUALITY, LIFE” and focus initiatives that benefit society, industry development and consumers. We are committed to maintaining this dedication for the long term.
Elanco is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. Since 1954, we rigorously innovate to improve the health of animals and benefit our customers.
Elanco has completed the acquisition of Bayer Animal health in 2020.8. Coming together with Bayer Animal Health makes an even better Elanco.
Together, we’re committed to providing a comprehensive suite of products along with unparalleled service and support to you, so you can do more for your beloved pets, make their life better.
MSD Animal Health
We believe, with deepening awareness that animal safety and human health are closely linked, Animal Health will have even better prospects for development with innovative high-quality animal drugs, vaccines, smart devices and services.
In Mainland China
MSD Animal Health has nearly 600 employees in China, with headquarters in Shanghai, factories in Ningbo and Tianjin, and R&D center in Ningbo
MSD Animal Health is made up of four business units: Poultry, Swine, Companion Animal, and Ruminant, which provides close to 60 products in our portfolio. We are committed to becoming a close partner of veterinarians, farmers and pet owners, improving animal health and benefiting Chinese society
Tianjin Ringpu Bio-Technology Co., Ltd. (referred to as "Ringpu"), founded in 1998, owns a total of 21 branch and subsidiary companies, 10 GMP approved production bases for veterinary drugs and 1 large-scale feed additive production base, 98 intelligent and modern large-scale production lines, and more than 500 kinds of animal products covering livestock, poultry and companion animals. It is China's largest manufacturer and service provider of animal health products with the most comprehensive product range, integrating biological products, pharmaceutical raw materials, pharmaceutical preparations and feed additives.
Bioally is the only domestic high-tech enterprise in China focused on developing, producing, and selling innovative drugs and functional healthcare products for pets. It has invested 250 million RMB to build a 24,000 square meter industrial base in Taizhou, China's Pharmaceutical City, meeting EU standards. In December 2023, it received approval for "Boshenjian," the world's first canine albumin .
Founded in 1956, HISUN PHARM is a comprehensive pharmaceutical enterprise featuring whole chain, multi-regional integration of research, production and marketing as well as development of drug substances and preparations. HISUN PHARM has 5 facilities, over 600 research staffs , over 60 unit labs，over 1100 patent applications (including 500+ invention patents) , which provides innovative results and quality products for the industry. As of 2021, Hisun Pharmaceutical is now one of the largest producers of antibiotics and anti-tumor drugs in China and has been listed in the Top 500 Chinese manufacturing enterprises and the Top 100 Chinese pharmaceutical enterprises multiple times.
As the holding subsidiary of HISUN PHARM, HISUN ANIMAL HEALTH (HISUNAH) inherits HISUN spirits and drug quality，has two production bases of Fuyang Chemical and Kunming Vaccine investing 800 million, which established lots of production lines （certificated by GMP and APVMA）. HISUNAH devotes to R&D, manufacture, sales and service, provides health solution for farm animal and companion animal. HISUNAH, live for animal health!
MISSON: INSIST ON DRUG INNOVATION, ACHIEVE HEALTH DREAM
VISION: TO BE A WIDELY RESPECTED GLOBAL PHARMACEUTICAL COMPANY
Slogan：Innovation，for animals，for health，for you.
Hanvet Biopharmaceutical Technology Co., Ltd. was established in 2008 and is located in Zhangjiang, Shanghai, known as "China's Silicon Valley". It is an internationally advanced high-tech enterprise integrating research, production, and sales of pet healthcare products. It has been recognized as a high-tech enterprise by the State three times in a row.
Hanvet has always adhered to the corporate values of "integrity, sincerity, dedication, innovation-driven, customer first, partner growth", deeply cultivating fields such as pet anti-infection, skin, urinary, fever and pain relief, and intestinal and external parasite control, as well as feline diseases, to provide systematic solutions and professional services for customers in the pet-specific new drugs, health care and care products.
The company strictly follows the international VICH & ICH guidelines to establish a professional animal drug R&D and testing center with a complete quality system; it builds factories in accordance with China's GMP and international GMP standards to provide 100% fully compliant pet-specific drugs.
To date, Hanvet has obtained 46 pet drug approvals, obtained 30 patent authorizations, 11 national new veterinary drug certificates, and contract-researched more than 30 formulas for international customers. With its trusted product quality and persistent investment in R&D, Hanwei Chongshi has become the loyal choice of more than 10,000 professional pet hospitals and has become "the pioneer of professional pet drugs in China".
Based in China and looking globally. Hanvet is committed to providing systematic solutions to safeguard pet health and build a harmonious world of human-pet friendship!
Founded in 1882, Candioli Pharma has celebrated 140 years of excellence in development and manufacturing of innovative products.
Candioli focuses on nutritional products for Companion Animals. Candioli Pharma relies upon its own specific competences, resulting from decades of experience, to produce state-of-the-art products, which have made the company a guarantee of high quality and expertise.
Candioli mission is to bring innovative solutions to Vets and Owners, so that Pets' Quality of Life can be more and more in line with the standards of our Society.
2018 saw the acquisition of Vetark, English company specialized in the production of feed supplement for Exotic animal. The new partnership will benefit greatly from shared industry knowledge, an enhanced product portfolio and extended international distribution.
In 2024, Candioli will officially announce its entry into the Chinese pet healthcare market at the WSAVA in Suzhou, China. As the exclusive importer for Candioli in this region, Candary (Shanghai) Enterprise Management Co., Ltd. is dedicated to introducing veterinary clinical products while providing strong support for the veterinary profession in China.
For inquiries in China, please contact: info@candary.co
Anlv Medical (AWALIFE) is a Shenzhen-based company that strategically integrates innovative research and development, precise manufacturing processes, and effective marketing strategies. Specializing in the swift development of In Vitro Diagnostic (IVD) devices and reagents specifically designed for the animal medical field, our overarching goal is to furnish pet clinics with advanced IVD solutions. We achieve this objective by harnessing independent and pioneering technologies.OUR PURPOSE--Healthcare for all.Our focus is on veterinary medicine, with the aim of delivering more precise results and expediting diagnostics to achieve a more comprehensive healthcare approach for all our animal companions.Our product:AI-100Vet is a unique automated device developed by Awalife for analyzing blood, feces, ascites, urine, and skin samples across various species, encompassing mammals, birds, and reptiles. This device offers a comprehensive solution for morphological examinations in pet hospitals
Hangzhou Evegen Biotech Co., Ltd is a R&D based biotech company, with high experienced technical team in genetic engineering, and IVD immunoassay field. We have well-established veterinary drug GMP facilities and biosafety level-II laboratories. All production activities are under control of ISO9001. ISO14001 and ISO45001.
Evegen has generated a brand called VETDiagnostix® for global market, and also a brand called "爱谨®" for Chinese local market. The two brands are served as a solution partner to the veterinary diagnostic practices for companion animals, farm animals and also wild animals. Under the brands, a wide range of product line are generated, which including canine, feline, exotic pet and so on.
BetaCat Intelligent Technology (Shanghai) Co., Ltd. is a digital healthcare company that combines deep expertise in medical software with a focus on innovative solutions. The company develops proprietary software and mini-programs as core products, integrating the brands Evet Software and Warmsoft. With a commitment to smart innovation, BetaCat aims to provide long-term high-quality products and services for veterinary hospitals and doctors.
Its wholly-owned subsidiary, Chongyi Buy, offers omnichannel marketing solutions that integrate online purchasing, inventory management, and offline O2O business models.
BetaCat focuses on the digitization field, aiming to provide faster, more precise, and deeper services to its partners through platform effects and integration.
Nanjing Jindun Animal Pharmaceutical Co., Ltd. (hereinafter referred to as Jindun Pharmaceutical), since 1991, has been developed on the basis of the Science and Technology Development Center of Nanjing Police Dog Research Institute of the Ministry of Public Security, and was established in 2003 to form Jindun Pharmaceutical, which has now developed into a high-tech enterprise integrating R&D, production, sales and service of pet drugs.
Relying on the authoritative and solid scientific research platform of national ministries and commissions, Jindun Pharmaceutical gives full play to the technical characteristics of police dogs, based on the unique needs of pet diagnosis and treatment and health care such as dogs and cats, and constantly innovates and explores to provide safe, efficient and excellent professional products for pets.
The company's product series cover skin diseases, eye diseases, ear diseases, heart diseases, hepatobiliary diseases, pet health care and other fields, serving 8,000 pet diagnosis and treatment institutions. "Pitfen" products are favored by customers and pet owners in the treatment of fungal skin diseases, and "Runkang", "Erkang" and other special drugs for the eyes and ears are widely known. All kinds of special products have been highly recognized by the market, so as to provide all-round protection for pet health.
The company adheres to market-oriented. The offline covers the sales network with pet diagnosis and treatment institutions as the main body, and the online authorization development e-commerce model provides professional consulting services for diagnosis and treatment institutions and pet owners, so that pets can easily enjoy the health care of Jindun Pharmaceutical.
Established in 1986 Inform Nutrition and our sister company Mervue Laboratories are global leaders in companion animal healthcare, producing nutrition-based healthcare solutions from our facilities in Ireland. To date we export to over 60 countries worldwide from both our facilities, where we are leading the global charge forward in sustainable companion animal nutraceuticals, which is at the core of our business values and practices.
At Inform Nutrition & Mervue Laboratories, we seek to develop innovative nutraceutical products that promote health and wellness with companion animals using sustainably sourced natural ingredients helping to enhance the performance of treatments within the veterinary setting, treating everyday healthcare issues.
With our world-class experienced team of pet nutritionists, veterinary doctors and scientists, we have formulated a high-quality range of innovative companion animal products that are inspired by nature but proven by science. Our companion animal nutraceutical range is formulated from a multi action approach with layers of added functionality to promote multiple pathways to target the source of the problem resulting in fast acting, highly effective outcomes for the target animal.
After close to 40 years in business, our teams in Inform Nutrition and Mervue Laboratories have a deep knowledge of Animal Nutrition given that we produce nutraceuticals for all species from production animals to equine and to companion animals. This knowledge transfer across the multiple species allows us to bring highly innovative ingredients and new delivery systems into our companion animal category.
Both our state-of-the-art manufacturing facilities are based in Cork Ireland, and operates under GMP+ to ensure the highest quality standards and full traceability.
ABOUT VETOQUINOL ：
Vetoquinol is a leading global animal health company, with operations in Europe, the Americas and Asia/Pacific. Independent and a pure player, Vetoquinol innovates, develops and markets veterinary medicines and non-medicated products for livestock (cattle, pigs) and companion animals (dogs, cats). Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and acquisitions made in high-potential territories ensure hybrid growth for the Group. At December 31, 2023, Vetoquinol employed 2,483 people. Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).
